Mesenkia Therapeutics AB
559443-7021ActiveDeveloping novel antibodies to treat aggressive brain cancer glioblastoma.
Overview
- 2
- Employees
- 0 SEK
- Revenue
- 2023
- Founded
Description
Mesenkia is a pre-clinical biotechnology company focused on developing breakthrough therapies for glioblastoma, an aggressive form of brain cancer. The company specializes in creating next-generation biological drug candidates, specifically single domain antibodies. Their scientific foundation stems...
Tags
Keywords
Company Information
- Industry
- Annan naturvetenskaplig och teknisk forskning och utveckling
- Legal Form
- Aktiebolag
- VAT Number
- SE559443702101
Decision Makers
No decision makers found yet
Similar Companies
20 similar companies in FunnelfeedrOblique Therapeutics AB (publ)
10–19 employeesInnovative biotech developing breakthrough antibodies using the AbiProt platform.
Sang Biotech AB
0 employeesDeveloping novel antibody therapeutics for kidney and cardiovascular diseases.
Affibody Medical AB
Developing next-generation radiopharmaceuticals using proprietary Affibody platform.
PILA PHARMA AB
1–4 employeesClinical stage biotech developing an oral obesity and diabetes treatment.
Affibody AB
50–99 employeesDeveloping next-generation radiopharmaceuticals using proprietary Affibody technology.
Browse More
Mesenkia Therapeutics AB Questions
Want to see Funnelfeedr in action?
Book a free demo and discover how Funnelfeedr helps you find and convert your ideal customers.
Book a demo